Combination pharmacotherapy for psychiatric disorders in children and adolescents: Prevalence, efficacy, risks and research needs

Pediatric Drugs

Volumn 15, Issue 5, 2013, Pages 377-391

  Jureidini, Jon ^a,c   Tonkin, Anne ^a   Jureidini, Elsa ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885571198     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0032-6     Document Type: Review

References (91)

1. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6(6):695-704.
2. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry. 2010;49:1001-10.
3. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics. Eur Neuropsychopharmacol. 2009;19(7):520-32.
4. Joshi G, Gerogiopoulos AM. Combination pharmacotherapy for psychiatric disorders in children and adolescents. Rosenberg DR, Gershon S (eds) Pharmacotherapy of child and adolescent psychiatric disorders, chap. 17. 3rd ed. New York: Wiley; 2012.
5. Pincus HA, Tew JD, First MB. Psychiatric comorbidity: is more less? World Psychiatry. 2004;3(1):18-23.
6. Beddoe R. Dying for a cure. New York: Random House; 2007.
7. Rashed AN, Wong ICK, Cranswick N, et al. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2011. doi: 10.1007/s00228-011-1183-4.
8. Kaminer Y, Goldberg P, Connor DF. Psychotropic medications and substances of abuse interactions in youth. Subst Abuse. 2010;31:53-7.
9. Muscatello MR, Spina E, Bandelow B, Baldwin DS. Clinical relevant drug interactions in anxiety disorders. Human Psychopharmacol Clin Exp. 2012. doi: 10.1002/hup.2217. Accessed 29 Mar 2012.
10. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86:203-15.
11. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Therap. 2008;30(7):1206-27.
12. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Safety. 2008;7:587-96.
13. Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Safety. 2002;25:91-110.
14. Chen H, Patel A, Sherer J, et al. The definition and prevalence of pediatric psychotropic polypharmacy. Pyschiatric Serv. 2011;62:1450-5.
15. McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. J Clin Psychiatry. 2009;70:240-6.
16. Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state medicaid program. Clin Therap. 2010;32(5):949-59.
17. Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolescent Psychopharmacol. 2006;16(3):273-85.
18. Griffith AK, Huscroft-D'Angelo J, Epstein MH, et al. Psychotropic medication use for youth in residential treatment: a comparison between youth with monopharmacy versus polypharmacy. J Child Fam Stud. 2010;19:795-802.
19. Russell PSS, George C, Mammen P. Predictive factors for polypharmacy among child and adolescent psychiatry inpatients. Clin Pract Epidemiol Mental Health. 2006;2:25.
20. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20:623-32.
21. Fontanella CA, Bridge JA, Campo JV. Psychotropic medication changes, polypharmacy and the risk of early readmission in suicidal adolescent inpatients. Ann Pharmacother. 2009;43:1939-47.
22. Zoega H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol. 2009;19:757-64.
23. Zito JM, Safer DJ, Jon-van den Berg LTW, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Mental Health. 2008;2:26.
24. Gerhard T, Chavez B, Olfson M, et al. National patterns of the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol. 2009;29:307-10.
25. Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1):e157-63.
26. Duffy FF, Narrow WE, Rae DS, et al. Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol. 2005;15:12-25.
27. National Collaborating Centre for Mental Health. CG72 Attention deficit hyperactivity disorder (ADHD): full guideline. UK: The British Psychological Society and The Royal College of Psychiatrists; 2009. http://www.nice.org.uk/ nicemedia/live/12061/42060/42060.pdf.
28. National Collaborating Centre for Mental Health. CG28 Depression in Children and Young People. Identification and management in primary, community and secondary care. UK: The British Psychological Society and The Royal College of Psychiatrists; 2005.
29. Martin A, Scahill L, Kratochvil C. Pediatric psychopharmacology principles and practice. 2nd ed. Oxford: Oxford University of Press; 2011.
30. Kutcher S, Chehil S. Physical treatments, Rutter's child and adolescent psychiatry. 5th ed. New York: Blackwell Publishing Limited; 2008.
31. Rosenberg D, Gershon S (eds) Pharmacotherapy of child and adolescent psychiatric disorders. 3rd ed. Chichester: John Wiley & Sons; 2012.
32. George JN, Vesely SK, Woolf SH. Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods. Am J Med Qual. 2013;20:1-8.
33. AACAP. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48:9.
34. Findling RL, McNamara NK, Gracious BL, et al. Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry. 2003;42(8):895-901.
35. Steering committee on quality improvement and subcommittee on attention-deficit/hyperactivity disorder. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007-22.
36. Safer DJ, Zito JM, dosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160:438-49.
37. Gittelman-Klein R, Klein DF, Katz S, Saraf K, et al. Comparative effects of methylphenidate and thioridazine in hyperkinetic children, I: clinical results. Arch Gen Psychiatry. 1976;33:1217-31.
38. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr. 2000;39:15-25.
39. Carlson GA, Rapport MD, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol. 1995;5:191-204.
40. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1-37.
41. Palumbo DR, Sallee FR, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180-8.
42. Kurlan R, Tourette's Syndrome Study Group. Treatment of ADHD in children with tics. Neurology. 2002;58:527-36.
43. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74-85.
44. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406-13.
45. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-24.
46. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:5.
47. Hazell P, Jairam R. Acute treatment of mania in children and adolescents. Curr Opin Psychiatry. 2012;25:264-70.
48. Cannon M, Pelham WH, Sallee R, CAT Study Team, et al. Effects of clonidine and methylphenidate on family quality of life in attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:511-7.
49. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886-94.
50. Perera H, Jeewandara KC, Seneviratne S, et al. ADHD refractory to methylphenidate treatment: a double-blind, placebo-controlled study combined Ω3 and Ω6 supplementation in children with attention-deficit hyperactivity disorder. J Child Neurol. 2012;27:747.
51. Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, et al. Acetyl-l-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev. 2011;42(3):367-75.
52. Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12):1392-401.
53. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558-65.
54. Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009;19(5):553-61.
55. Scheffer RE, Kowatch RA, Carmody TC, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilisation with divalproex sodium. Am J Psychiatry. 2005;162:58-64.
56. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4:9.
57. Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol. 2011;21(1):1-19.
58. Farmer CA, Arnold LE, Bukstein OG, Findling RL, et al. The treatment of severe child aggression (TOSCA) study: design challenges. Child Adolesc Psychiatry Ment Health. 2011;5(1):36.
59. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216-23.
60. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):32-6.
61. Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1269-72.
62. Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31(5):369-75.
63. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501-10.
64. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215-26.
65. Wilens TE, Hammerness P, Utziner L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009;19(5):485-92.
66. Snyder R, Turgay A, Aman M, Risperidone Conduct Study Group, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatr. 2002;41(9):1026-36.
67. Aman MG, DeSmedt G, Derivan A, The Risperidone Disruptive Behavior Study Group, et al. Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159:1337-46.
68. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14(2):243-54.
69. Kronenberger WG, Giauque AL, Lafata DE, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334-47.
70. Chang K, Nayar D, Howe M, et al. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009;19(5):547-51.
71. Findling RL, McNamara NK, Stansbrey R, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom restabilisation. J Am Acad Child Adolesc Psychiatry. 2006;45(2):142-8.
72. Kafantaris V, Coletti DJ, Dicker R, et al. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatryr. 2001;40(12):1448-56.
73. Kafantaris V, Dicker R, Coletti DJ, et al. Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J Child Adolesc Psychopharmacol. 2001;11(4):409-13.
74. Kowatch RA, Sethuraman G, Hume JH, Kromelis M, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 2003;53(11):978-84.
75. Pavuluri MN, Henry DB, Carbray JA, et al. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord. 2004;82(Suppl 1):S103-11.
76. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):298-304.
77. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574-9.
78. Shamseddeen W, Clarke G, Keller MB, et al. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012;22(1):29-36.
79. Kondo DG, Sung YH, Hellem TL, et al. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord. 2011;135(1-3):354-61.
80. Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19(5):539-45.
81. Hammerness P, Georgiopoulos A, Doyle R, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009;19(5):493-9.
82. Calarge CA, Acion L, Kuperman S, et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19(2):101-9.
83. Bahk WM, Shin YC, Woo JM, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prof Neuropsychopharmacol Biol Psychiatry. 2005;29(1):115-21.
84. Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder. Adv Ther. 2012;29(5):385-400.
85. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19(5):563-73.
86. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;41(1):65-73.
87. Safer D. Age-grouped differences in adverse drug events from psychotropic medication. J Child Adolesc Psychopharmacol. 2004;21(4):299-309.
88. Jureidini J. Key opinion leaders in psychiatry: a conflicted pathway to career advancement. Aust N Z J Psychiatry. 2012;46:495-7.
89. Cutting edge information. Key opinion leaders (PH122) relationship management and segmentation data. 2009 Extracts. http://www.cuttingedgeinfo.com/ research/medical-affairs/key-opinion-leaders/. Accessed Feb 2012 (Full copy available from Jon Jureidini).
90. Allen S. Backlash on bipolar diagnoses in children: MGH psychiatrist's work stirs debate. Boston Globe June 17, 2007. http://www.boston.com/yourlife/ health/diseases/articles/2007/06/17/backlash-on-bipolar-diagnoses-in-children/.
91. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-9.